Efficacy of oral etoposide in pretreated metastatic breast cancer

Medicine (United States)

Volumn 94, Issue 17, 2015, Pages e774-

  Yuan, Peng ^a   Di, Lijun ^b   Zhang, Xiaohui ^c   Yan, Min ^d   Wan, Donggui ^e   Li, Li ^f   Zhang, Yongqiang ^g   Cai, Jufen ^h   Dai, Hong ⁱ   Zhu, Qi ^j   Hong, Ruoxi ^a   Xu, Binghe ^a  

^a CANCER HOSPITAL   (China)

^b PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^c PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^d Henan Cancer Hospital   (China)

^e CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

^f DALIAN MEDICAL UNIVERSITY   (China)

^g BEIJING HOSPITAL   (China)

^h ZHEJIANG CANCER HOSPITAL   (China)

ⁱ CAPITAL MEDICAL UNIVERSITY   (China)

^j People s Hospital of Shanghai Putuo District   (China)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ETOPOSIDE; TAXANE DERIVATIVE; ANTHRACYCLINE; TAXOID;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER PATIENT; CHINESE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; KIDNEY FUNCTION; LEUKOPENIA; LIVER FUNCTION; MAJOR CLINICAL STUDY; METASTATIC BREAST CANCER; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOCYTOPENIA; TREATMENT PLANNING; TREATMENT RESPONSE; VOMITING; BREAST NEOPLASMS; CHINA; CLINICAL TRIAL; DISEASE COURSE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; SALVAGE THERAPY; SURVIVAL RATE; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; ANTHRACYCLINES; BREAST NEOPLASMS; CHINA; DISEASE PROGRESSION; ETOPOSIDE; FEMALE; HUMANS; MIDDLE AGED; SALVAGE THERAPY; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME;

EID: 84937511431     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000000774     Document Type: Article

References (24)

1. Nistico C, Garufi C, Milella M, et al. Weekly schedule of vinorelbine in pretreated breast cancer patients. Breast Cancer Res Treat. 2000;59:223-229.
2. Talbot DC, Moiseyenko V, Van Belle S, et al. Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br J Cancer. 2002;86:1367-1372.
3. Smorenburg CH, Bontenbal M, Seynaeve C, et al. Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxane. Breast Cancer Res Treat. 2001;66:83-87.
4. Zelek L, Barthier S, Riofrio M, et al. Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma. Cancer. 2001;92:2267-2272.
5. Spielmann M, Llombart-Cussac A, Kalla S, et al. Single-agent gemcitabine is active in previously treated metastatic breast cancer. Oncology. 2001;60:303-307.
6. Henwood JM, Brogden RN. Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer. Drugs. 1990;39:438-490.
7. Schell FC, Yap HY, Hortobagyi GN, et al. Phase II study of VP16- 213 (etoposide) in refractory metastatic breast carcinoma. Cancer Chemother Pharmacol. 1982;7:223-225.
8. Slevin ML, Clark PI, Joel SP, et al. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J Clin Oncol. 1989;7:1333-1340.
9. Hill BT, Whelan RD, Rupniak HT, et al. A comparative assessment of the in vitro effects of drugs on cells by means of colony assays or flow microfluorimetry. Cancer Chemother Pharmacol. 1981;7:21-26.
10. Comis RL. Oral etoposide in oncology: an evolving role. Ann Oncol. 1992;3 (suppl 3):63-67.
11. Hainsworth JD, Johnson DH, Frazier SR, et al. Chronic daily administration of oral etoposide: a phase I trial. J Clin Oncol. 1989;7:396-401.
12. Hainsworth JD, Johnson DH, Frazier SR, et al. Chronic daily administration of oral etoposide in refractory lymphoma. Eur J Cancer. 1990;26:818-821.
13. Sledge GW Jr. Etoposide in the management of metastatic breast cancer. Cancer. 1991;67 (suppl 1):266-270.
14. Neskovic-Konstantinovic ZB, Bosnjak SM, Radulovic SS, et al. Daily oral etoposide in metastatic breast cancer. Anticancer Drugs. 1996;7:543-547.
15. Martin M, Lluch A, Casado A, et al. Clinical activity of chronic oral etoposide in previously treated metastatic breast cancer. J Clin Oncol. 1994;12:986-991.
16. Bontenbal M, Planting AS, Verweij J, et al. Second-line chemotherapy with long-term low-dose oral etoposide in patients with advanced breast cancer. Breast Cancer Res Treat. 1995;34:185-189.
17. Calvert AH, Lind MJ, Millward MM, et al. Long-term oral etoposide in metastatic breast cancer: clinical and pharmacokinetic results. Cancer Treat Rev. 1993;19 (suppl C):27-33.
18. Palombo H, Estape J, Vinolas N, et al. Chronic oral etoposide in advanced breast cancer. Cancer Chemother Pharmacol. 1994;33:527-529.
19. Yuan Peng, Xu BnghBing-he, Wang -y, et al. Oral etoposide monotherapy is effective for metastatic breast cancer with heavy prior therapy. Chin Med J. 2012;125:775-779.
20. Ross W, Rowe T, Glisson B, et al. Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage. Cancer Res. 1984;44 (12 pt 1):5857-5860.
21. Pusztai L, Walters RS, Valero V, et al. Daily oral etoposide in patients with heavily pretreated metastatic breast cancer. Am J Clin Oncol. 1998;21:442-446.
22. Saphner T, Weller EA, Tormey DC, et al. 21-day oral etoposide for metastatic breast cancer: a phase II study and review of the literature. Am J Clin Oncol. 2000;23:258-262.
23. Jagodic M, Cufer T, Zakotnik B, et al. Selection of candidates for oral etoposide salvage chemotherapy in heavily pretreated breast cancer patients. Anticancer Drugs. 2001;12:199-204.
24. Erkisi M, Bilkay BC, Seyrek E, et al. Refractory breast cancer: a comparison of two different chemotherapy regimens. J Chemother. 1997;9:442-445.